Swayam R. Prakash

Cardiology

7111 Medical Center Dr Ste 200
Texas City,, TX 77591

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 115 publications

CCL25 chemokine promotes antiviral tissue resident CD4+ and CD8+ effector memory TRM cells associated with a reduction of ocular herpes infection and disease: a potential gut-eye axis in herpes immunity.

CCL25 chemokine promotes antiviral tissue resident CD4+ and CD8+ effector memory TRM cells associated with a reduction of ocular herpes infection and disease: a potential gut-eye axis in herpes immunity.

Journal: Frontiers in immunology

Published: May 04, 2026

A Multi-Antigen Broad-Spectrum Coronavirus Vaccine Induces Potent and Durable Cross-Protection Against Infection and Disease Caused by Multiple SARS-CoV-2 Variants.

A Multi-Antigen Broad-Spectrum Coronavirus Vaccine Induces Potent and Durable Cross-Protection Against Infection and Disease Caused by Multiple SARS-CoV-2 Variants.

Journal: Research square

Published: September 02, 2025

Insights into Persistent SARS-CoV-2 Reservoirs in Chronic Long COVID.

Insights into Persistent SARS-CoV-2 Reservoirs in Chronic Long COVID.

Journal: Viruses

Published: August 25, 2025

NF-κB/OCT-1 Mediated Upregulation of CXCL14 Chemokine Mobilizes Mucosal Effector Memory CD44+CD62L-CD4+ and CD8+ TEM Cells, and NK Cells Associated with Protection Against Genital Herpes.

NF-κB/OCT-1 Mediated Upregulation of CXCL14 Chemokine Mobilizes Mucosal Effector Memory CD44+CD62L-CD4+ and CD8+ TEM Cells, and NK Cells Associated with Protection Against Genital Herpes.

Journal: Pathogens & immunity

Published: August 11, 2025

Artificial intelligence-, organoid-, and organ-on-chip-powered models to improve pre-clinical animal testing of vaccines and immunotherapeutics: potential, progress, and challenges.

Artificial intelligence-, organoid-, and organ-on-chip-powered models to improve pre-clinical animal testing of vaccines and immunotherapeutics: potential, progress, and challenges.

Journal: Frontiers in artificial intelligence

Published: August 06, 2025

The Path Towards Effective Long-Lasting Tissue-Targeted Prime/Pull/Keep Herpes Simplex Therapeutic Vaccines.

The Path Towards Effective Long-Lasting Tissue-Targeted Prime/Pull/Keep Herpes Simplex Therapeutic Vaccines.

Journal: Vaccines

Published: July 28, 2025

Role of mucosal chemokines in the development of tissue-resident CD4+ and CD8+ TRM cells to fend off herpes simplex infections.

Role of mucosal chemokines in the development of tissue-resident CD4+ and CD8+ TRM cells to fend off herpes simplex infections.

Journal: Frontiers in immunology

Published: July 08, 2025

A pan-beta-coronavirus vaccine bearing conserved and asymptomatic B- and T-cell epitopes protects against highly pathogenic Delta and highly transmissible Omicron SARS-CoV-2 variants.

A pan-beta-coronavirus vaccine bearing conserved and asymptomatic B- and T-cell epitopes protects against highly pathogenic Delta and highly transmissible Omicron SARS-CoV-2 variants.

Journal: Human vaccines & immunotherapeutics

Published: July 04, 2025

Artificial intelligence and machine learning in the development of vaccines and immunotherapeutics-yesterday, today, and tomorrow.

Artificial intelligence and machine learning in the development of vaccines and immunotherapeutics-yesterday, today, and tomorrow.

Journal: Frontiers in artificial intelligence

Published: April 29, 2025

CXCL13/CXCR5 chemokine axis promotes antiviral CXCR5+CD19+ B Cells and follicular/effector CXCR5+CD4+ T Cells in the lungs associated with protection from severe and fatal COVID-19 following infection with pathogenic SARS-CoV-2 Delta variant.

CXCL13/CXCR5 chemokine axis promotes antiviral CXCR5+CD19+ B Cells and follicular/effector CXCR5+CD4+ T Cells in the lungs associated with protection from severe and fatal COVID-19 following infection with pathogenic SARS-CoV-2 Delta variant.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: April 21, 2025

A tissue-targeted prime/pull/keep therapeutic herpes simplex virus vaccine protects against recurrent ocular herpes infection and disease in HLA-A*0201 transgenic rabbits.

A tissue-targeted prime/pull/keep therapeutic herpes simplex virus vaccine protects against recurrent ocular herpes infection and disease in HLA-A*0201 transgenic rabbits.

Journal: Journal of virology

Published: April 10, 2025

Therapeutic mucosal vaccination of herpes simplex virus type 2 infected guinea pigs with an adenovirus-based vaccine expressing the ribonucleotide reductase 2 and glycoprotein D induces local tissue-resident CD4+ and CD8+ TRM cells associated with protection against recurrent genital herpes.

Therapeutic mucosal vaccination of herpes simplex virus type 2 infected guinea pigs with an adenovirus-based vaccine expressing the ribonucleotide reductase 2 and glycoprotein D induces local tissue-resident CD4+ and CD8+ TRM cells associated with protection against recurrent genital herpes.

Journal: Frontiers in immunology

Published: January 29, 2025

Showing 1-12 of 115

Last Updated: 09/26/2026